[
  {
    "ts": "2026-01-09T01:10:02+00:00",
    "headline": "Moderna (MRNA) Is Up 14.8% After Filing Global Applications For Its mRNA Flu Vaccine mRNA-1010",
    "summary": "In early January 2026, Moderna filed for marketing authorization of its investigational seasonal influenza vaccine mRNA-1010 in the US, EU, Canada, and Australia for adults aged 50 and older, supported by positive Phase 3 data showing relative vaccine efficacy of about 27% and a favorable safety profile. This move marks a key test of Moderna’s effort to extend its mRNA platform beyond COVID-19, potentially broadening its respiratory vaccine portfolio and reducing reliance on a single product...",
    "url": "https://finance.yahoo.com/news/moderna-mrna-14-8-filing-011002575.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "f810bbff-cf92-3ca7-98bf-e2b359cab18c",
      "content": {
        "id": "f810bbff-cf92-3ca7-98bf-e2b359cab18c",
        "contentType": "STORY",
        "title": "Moderna (MRNA) Is Up 14.8% After Filing Global Applications For Its mRNA Flu Vaccine mRNA-1010",
        "description": "",
        "summary": "In early January 2026, Moderna filed for marketing authorization of its investigational seasonal influenza vaccine mRNA-1010 in the US, EU, Canada, and Australia for adults aged 50 and older, supported by positive Phase 3 data showing relative vaccine efficacy of about 27% and a favorable safety profile. This move marks a key test of Moderna’s effort to extend its mRNA platform beyond COVID-19, potentially broadening its respiratory vaccine portfolio and reducing reliance on a single product...",
        "pubDate": "2026-01-09T01:10:02Z",
        "displayTime": "2026-01-09T01:10:02Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/759f0ca28b885d5d534769cdaccce534",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lV6Oo0M_C3X63uXoBkpnwQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/759f0ca28b885d5d534769cdaccce534.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/KdbFtaQiMRVA6Enl712wNA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/759f0ca28b885d5d534769cdaccce534.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/moderna-mrna-14-8-filing-011002575.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/moderna-mrna-14-8-filing-011002575.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRNA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]